Recently, many patients with myeloproliferative neoplasms (MPNs) have often asked if a new drug is available? Some patients have looked online to see how the 2015 study of the U.S. drug for JAK2-positive-ruxolitinib actually works? Reports from the 2015 American Society of Hematology Annual Meeting (ASH) state that the FDA approved the JAK2 inhibitor-ruxolitinib (Jakafi Incyte) in 2011 for the treatment of patients with moderate-to-high-risk myelofibrosis (MF); it was approved in December 2014 for patients with true erythroblastosis (PV) who are hydroxyurea intolerant or resistant. Patients with PV with combined splenomegaly, bleeding dependence, and hydroxyurea resistance or intolerance are considered an ideal population for treatment with JAK2 inhibitors. About 1/4 of patients are resistant or intolerant to hydroxyurea. At 3-year follow-up of MF applications, half of the patients with MF adhered to treatment, and 50-80% had a reduced spleen that did not change the course of the disease. There are still many aspects of ruxolitinib that need to be confirmed: how safe it is for long-term use; when it can be discontinued due to its high price; whether it relapses after discontinuation; whether it provides durable spleen reduction and symptom relief; whether it can change the histopathology of the bone marrow; and whether overall survival can be improved. For our patients with myeloproliferative neoplasms (MPNs) true erythroblastosis (PV), essential thrombocythemia (ET) and myelofibrosis (MF), it will still take time for real access to ruxolitinib, except for economic reasons. Resistance or intolerance to hydroxyurea includes: lower extremity ulcers, mouth sore ulcers, acne, gastrointestinal symptoms, pneumonia and fever.